Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-10
2007-07-10
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S410000, C514S406000, C514S274000, C514S255050, C514S232800, C548S417000, C548S358100, C544S316000, C544S405000, C544S111000, C546S275700
Reexamination Certificate
active
11017915
ABSTRACT:
The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.
REFERENCES:
patent: 5475110 (1995-12-01), Hudkins et al.
patent: 5591855 (1997-01-01), Hudkins et al.
patent: 5594009 (1997-01-01), Hudkins et al.
patent: 5616724 (1997-04-01), Hudkins et al.
patent: 5705511 (1998-01-01), Hudkins et al.
patent: 6630500 (2003-10-01), Gingrich et al.
patent: 2004/0048915 (2004-03-01), Engler et al.
patent: 2005/0143442 (2005-06-01), Hudkins et al.
patent: WO 96/11933 (1996-04-01), None
patent: WO 98/07433 (1998-02-01), None
patent: WO 00/47583 (2000-08-01), None
patent: WO 02/17914 (2002-03-01), None
patent: WO 02/28861 (2002-04-01), None
patent: WO 02/28874 (2002-04-01), None
patent: WO 02/30942 (2002-04-01), None
patent: WO 02/092065 (2002-11-01), None
patent: 0 545 195 (2003-06-01), None
Folkman, J. “Anti-Angiogenesis: New Concept for Therapy of Solid Tumors”, Ann. Surg. vol. 175, No. 3, 1972.
Angeles, et al., “Enzyme-linked immunosorbent assay for trkA tyrosine kinase activity,”Anal. Biochem., 1996, 236, 49-55.
Hudkins, R.L., et al., “Synthesis of benzo[b]furano-[2,3-a]pyrrolo[3,4-c]carbazole-5,-7-dione,” J.Heterocyclic Chemistry, 2001, 38, 591-595.
Hudkins, R.L., “Synthesis of indeno[2,1-a]pyrrolo[3,4-c]carbzole lactam regioisomers using ethyl cis-β-cyanoacrylate as a dienophile and lactam precursor,” J.Heterocyclic Chemistry, 2003, 40, 135-142.
J. Chem. Res., 1986, 1401-1445.
Lehninger, A.L., “The amino acid building blocks of proteins,” The Molecular Basis of Cell Structure and Function,Biochemistry, 2ndEd. Worth Publishers, NY, 1975, 71-77.
Merritt, S.E., et al., “The mixed lineage kinase DLK utilizes MKK7 and not MKK4 as substrate,”J. Biol. Chem., 1999, 274(15), 10195-10202.
Peet, N., et al., “Synthesis of angular benzodipyrazoles and related systems,”Heterocycles, 1991, 32(1), 41-72.
Pitt, A.M., et al., “High throughput screening protein kinase assays optimized for reaction, binding, and detection totally within a 96-well plate,”J. of Biomol. Screening, 1996, 1(1), 47-51.
Rotin, et al., “SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity biding site for SH2 domains of phospholipase C-γ,”EMBO J., 1992, 11(2), 559-567.
Rovin, L.J., “Preformulation,”Remington's Pharmaceutical Sciences, 17thEd., Mack Publishing Co., Easton, PA, 1985, Chapter 76, 1409-1423.
Schenone, P., et al., “Reaction of 2-dimethylaminomethylene-1,3-diones with dinucleophiles. I. Synthesis of 1,5-disubstituted 4-acylpyrazoles,”J. Heterocyclic Chem., 1982, 19, 1355-1361.
Wynne, J.H., et al., “Facile one-pot synthesis ofS-alkyl thiocarbamates,”J. Org. Chem., 2003, 68, 3733-3735.
Engler, T.A., et al., “Novel, potent and selective cynclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles,”Bioorganic&Medicinal Chem. Letts., 2003, 13:2261-2267.
Gingrich, D.E., et al., “A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055,”J. Med. Chem., 2003, 46, 5375-5388, Dec. 18, 2003.
Laird, A.D., et al., “Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents,”Expert. Opin. Investig. Drugs, 2003, 12(1), 51-64, Jan. 2003.
Ruggeri, B., et al., “CEP-7055: A novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models,”Cancer Res., 2003, 63, 5978-5991, Sep. 15, 2003.
Sanchez-Martinez, C., et al., “Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors,”Bioorganic&Medicinal Chem. Letts., 2003, 13, 3835-3839.
Hudkins Robert L.
Reddy Dandu R.
Tao Ming
Underiner Theodore L.
Zulli Allison L.
Barker Michael
Cephalon Inc.
McKane Joseph K.
Woodcock & Washburn LLP
LandOfFree
Fused pyrrolocarbazoles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused pyrrolocarbazoles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused pyrrolocarbazoles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3773714